The Global Task Force for the Universal Definition of Myocardial Infarction and the National Academy of Clinical Biochemistry recommend the 99th percentile of cardiac troponin as a diagnostic threshold, provided that assay precision can be demonstrated to have a CV of Յ10% at this concentration (1 ) . To determine the 99th percentile, we applied a high-sensitivity cardiac troponin I (hscTnI) assay (Abbott Diagnostics) to an analysis of a cohort of young, apparently healthy Asian women with low cardiovascular risk, and correlated this result with demographic and clinical characteristics to identify factors associated with higher cTnI concentrations.
The cohort was obtained from our hospital staff health-screening program. Fasting serum samples were stored at Ϫ70°C for up to 6 months until analysis. Nonpregnant women 20 -65 years of age with no self-reported personal history of heart disease, diabetes, or hypertension were selected for analysis of cTnI concentrations with the Abbott ARCHITECT i4000 analyzer and a premarket prototype hscTnI assay. Institutional review board approval was obtained for this study (DSRB/2011/01931).
SPSS version 19 (SPSS/IBM) was used for statistical analyses. We calculated precision from measurements obtained over 15 days with 10 dilutions of pooled serum (cTnI concentration, 1.0 -110 ng/L). After removal of 2 outliers, we calculated the 99th percentile for the remaining data with a nonparametric method. The Student t-test and ANOVA were used to evaluate the statistical significance of the differences in cTnI concentrations with respect to smoking status, family history, metabolic syndrome, and ethnic groups. Multivariate logistic regression analysis was used to evaluate the relationships of the cTnI concentration to age, systolic blood pressure, waist circumference, Letters to the Editor body mass index, total cholesterol, triglycerides, and fasting glucose. cTnI concentrations Ն4.0 ng/L were measured with a CV of Յ10%. cTnI was measurable (nonzero) in 99% of all individuals, and the cTnI data had a log-normal distribution. The 99th percentile was 4.8 ng/L (95% CI, 4.4 -10.4 ng/L), with a measurement CV of 9%.
The cTnI concentrations were divided into quartiles and presented according to the various demographic and clinical characteristics ( Table 1) . cTnI concentration was significantly associated with age but not with ethnic group. Smokers had a higher mean cTnI concentration (2.2 ng/L) compared with nonsmokers (1.4 ng/L, difference not statistically significant). There was no statistically significant difference in cTnI concentrations between women with a selfreported family history of heart disease and those without such a history.
cTnI concentration was correlated with systolic blood pressure, BMI, waist circumference, total cholesterol, LDL cholesterol, triglycerides, and fasting glucose ( Table 1) . The mean (SD) cTnI concentration for women with metabolic syndrome (as defined by the National Cholesterol Education Program Adult Treatment Panel III report) was 2.2 (0.9) ng/L, which was significantly higher than those without metabolic syndrome [1.4 (1.3) ng/L; P ϭ 0.012)]. The 10-year risk for coronary heart disease calculated with the Framingham system was also associated significantly with cTnI concentration.
We chose a female-only cohort because males have a higher risk of cardiovascular disease and because troponin concentrations are higher in healthy men than in women (2 ) . The 99th percentile of cTnI obtained with this cohort (4.8 ng/L) is much lower than reported elsewhere for other women tested with the same assay (15 ng/L) (2 ) . This discrepancy could be attributed to the very low cardiovascular risk in this cohort of young healthy women. Given that the hscTnI assay was still under development at the time of the study, differences in assay characteristics, calibrations, or performance with different analyzers might also explain the discrepancy in reference cTnI concentrations. The CV of Յ10% for this assay at the 99th percentile fulfills the criteria for a highsensitivity cardiac troponin assay (3) .
Population studies that have demonstrated the utility of cardiac troponin for predicting cardiovascular mortality have shown troponin concentration to be associated with increasing systolic blood pressure, body mass index, and triglyceride concentrations (4, 5 ) . In this study, cTnI concentration was associated with such cardiovascular risk factors as waist circumference, body mass index, cholesterol, and fasting glucose at healthy values for these risk factors. Taken together, these studies show that higher cardiac troponin concentrations as measured with high-sensitivity cardiac troponin assays are associated with a greater burden of cardiovascular risk. The increase in cardiovascular risk factors may be associated with a proinflammatory state, leading to increased cardiomyocyte turnover and an increased background release of cTnI. Of interest would be to study the concentrations of proinflammatory biomarkers, such as C-reactive protein as measured with a highsensitivity assay, to assess the contribution of subclinical inflammation associated with cardiometabolic risk to the cTnI concentration. A limitation of this study is that the cohort was not assessed objectively for cardiovascular and renal functions. Further studies are needed to determine whether there is a role for high-sensitivity cardiac troponin in screening young adults for the purpose of primary prevention. 
